請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56024完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Shih-Chun Lu | en |
| dc.contributor.author | 陸世君 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:13:18Z | - |
| dc.date.available | 2019-10-20 | |
| dc.date.copyright | 2014-10-20 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-18 | |
| dc.identifier.citation | [1] 'World Health Organization. Mortality Database. WHO Statistical Information System. 2008.'.
[2] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F., 'GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]'. [3] Venook AP, Papandreou C, Furuse J, de Guevara LL., 'The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective'.Oncologist. 2010;15 Suppl 4:5-13. [4] Liu CJ, Kao JH., 'Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors'.J Chin Med Assoc. 2007 Apr;70(4):141-5. [5] Chen CJ, Yu MW, Liaw YF., 'Epidemiological characteristics and risk factors of hepatocellular carcinoma'.J Gastroenterol Hepatol. 1997 Oct;12(9-10):S294-308. [6] Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC., 'Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants'.J Formos Med Assoc. 2007 Feb;106(2):148-55. [7] Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS., 'Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group'.N Engl J Med. 1997 Jun 26;336(26):1855-9.. [8] Ming-Whei Yu, Shiou-Hwei Yeh, Pei-Jer Chen, Yun-Fan Liaw, Chih-Lin Lin, Chun-Jen Liu, Wei-Liang Shih, Jia-Horng Kao, Ding-Shinn Chen and Chien-Jen Chen, 'Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men'.J Natl Cancer Inst (2005) 97 (4): 265-272. [9] Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group., 'Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level'.JAMA. 2006 Jan 4;295(1):65-73.. [10] Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, Chen CJ., 'Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men'.Carcinogenesis. 2008 Jan;29(1):106-12. [11] Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, Cheung KK, Wong EW, Wong VW., 'Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma'.Aliment Pharmacol Ther. 2013 Mar;37(5):517-26. [12] Kao JH, Chen PJ, Lai MY, Chen DS., 'Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B'.Gastroenterology. 2000 Mar;118(3):554-9. [13] Liao Y1, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L., 'Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis'.PLoS One. 2012;7(6):e38394. [14] Kao JH, Chen PJ, Lai MY, Chen DS., 'Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers'.Gastroenterology. 2003 Feb;124(2):327-34. [15] Herceg Z, Paliwal A., 'Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome'.Mutat Res. 2011 May-Jun;727(3):55-61. [16] Winter J, Jung S, Keller S, Gregory RI, Diederichs S., 'Many roads to maturity: microRNA biogenesis pathways and their regulation'.Nat Cell Biol. 2009 Mar;11(3):228-34. [17] Isaac Bentwich, 'A postulated role for microRNA in cellular differentiation'.The FASEB Journal. [18] Inui M, Martello G, Piccolo S, 'MicroRNA control of signal transduction'.Nat Rev Mol Cell Biol. 2010 Apr; 11(4):252-63. [19] Jovanovic M, Hengartner MO., 'miRNAs and apoptosis: RNAs to die for'.Oncogene. 2006 Oct 9;25(46):6176-87. [20] Garzon R, Calin GA, Croce CM., 'MicroRNAs in Cancer'.Annu Rev Med. 2009;60:167-79. [21] Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A., 'miR-221 overexpression contributes to liver tumorigenesis'.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9. [22] Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K., 'Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues'.Oncogene. 2006 Apr 20;25(17):2537-45. [23] Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J., 'Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma'.Int J Cancer. 2008 Oct 1;123(7):1616-22. [24] Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD., 'Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival'.Clin Cancer Res. 2008 Jan 15;14(2):419-27. [25] Jian Zhou, Lei Yu, Xue Gao, Jie Hu, Jiping Wang, Zhi Dai, Jie-Fei Wang, Zhiyong Zhang, Shaohua Lu, Xiaowu Huang, Zheng Wang, Shuangjian Qiu, Xiaoying Wang, Guohuan Yang, Huichuan Sun, Zhaoyou Tang, Ying Wu, Hongguang Zhu and Jia Fan, 'Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma'.J Clin Oncol. 2011 Dec 20;29(36):4781-8. [26] Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K., 'Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma'.Cancer Res. 2010 Dec 1;70(23):9798-807. [27] Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D., 'Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis'.Mol Carcinog. 2011 Feb;50(2):136-42. [28] Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T., 'Identification of tissue-specific microRNAs from mouse'.Curr Biol. 2002 Apr 30;12(9):735-9. [29] Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS., 'Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties'.Oncogene. 2009 Oct 8;28(40):3526-36. [30] Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, Chen L, Chen Y, Duan Z, Meng S., 'miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV'.Biochem Biophys Res Commun. 2010 Aug 6;398(4):771-7. [31] Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L, 'MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells'.Cancer Res. 2009 Jul 15;69(14):5761-7. [32] Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K., 'MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib'.J Biol Chem. 2009 Nov 13;284(46):32015-27. [33] Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, Tsai KS, Yu MW., 'Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression'.Gastroenterology. 2009 Nov;137(5):1687-97. [34] Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E., 'Clinical evaluation of microRNA expression profiling in non small cell lung cancer'.Lung Cancer. 2013 Sep;81(3):388-96. [35] Gao J, Zhang Q, Xu J, Guo L, Li X., 'Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA.'.Chin J Cancer Res. 2013 Dec;25(6):743-8. [36] Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N., 'MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer'.BMC Cancer. 2010 Apr 29;10:173. doi: 10.1186/1471-2407-10-173. [37] Liang Y, Ridzon D, Wong L, Chen C., 'Characterization of microRNA expression profiles in normal human tissues'.BMC Genomics. 2007 Jun 12;8:166. [38] Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J., 'Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?'.World J Urol. 2014 Apr;32(2):353-8. [39] Zhu W, Qin W, Atasoy U, Sauter ER., 'Circulating microRNAs in breast cancer and healthy subjects'.BMC Res Notes. 2009 May 19;2:89. [40] Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, Muller SC, Ellinger J., 'Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma'.Cancer Epidemiol. 2012 Aug;36(4):391-4. [41] Sanders I, Holdenrieder S, Walgenbach-Brunagel G, von Ruecker A, Kristiansen G, Muller SC, Ellinger J., 'Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma'.Int J Urol. 2012 Nov;19(11):1017-25. [42] Sourvinou IS, Markou A, Lianidou ES., 'Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability'.J Mol Diagn. 2013 Nov;15(6):827-34. [43] Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S., 'Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity'.Hepatology. 2012 Mar;55(3):730-41. [44] Changfei Li, Yanzhong Wang, Saifeng Wang, Bo Wu, Junli Hao, Hongxia Fan, Ying Ju, Yuping Ding, Lizhao Chen, Xiaoyu Chu, Wenjun Liu, Xin Ye and Songdong Meng, 'Hepatitis B Virus mRNA-Mediated miR-122 Inhibition Upregulates PTTG1-Binding Protein, Which Promotes Hepatocellular Carcinoma Tumor Growth and Cell Invasion'.J. Virol. February 2013 vol. 87 no. 4 2193-2205. [45] Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T., 'Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells'.Hepatology. 2013 Nov;58(5):1681-92. [46] Feng Peng, Xinqiang Xiao, Yongfang Jiang, Kaizhong Luo, Yi Tian, Milin Peng, Min Zhang, Yun Xu, Guozhong Gong, 'HBx Down-Regulated Gld2 Plays a Critical Role in HBV-Related Dysregulation of miR-122'.PLoS One 2014 25;9(3):e92998. . [47] Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S., 'Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity'.Hepatology. 2012 Mar;55(3):730-41. [48] Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, Hao Q, Liu Y, Gong H, Zhu Y, Liu F, Wu J., 'A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication'.FASEB J. 2011 Dec;25(12):4511-21. [49] Siaj R, Sauer V, Stoppeler S, Gers J, Spiegel HU, Kohler G, Zibert A, Schmidt HH., 'Longitudinal analysis of serum miR-122 in a rat model of Wilson's disease'.Hepatol Int. 2012 Oct;6(4):770-777. [50] Hu J, Wang Z, Tan CJ, Liao BY, Zhang X, Xu M, Dai Z, Qiu SJ, Huang XW, Sun J, Sun QM, He YF, Song K, Pan Q, Wu Y, Fan J, Zhou J., 'Plasma microRNA, a potential biomarker for acute rejection after liver transplantation'.Transplantation. 2013 Apr 27;95(8):991-9. [51] Shifeng H, Danni W, Pu C, Ping Y, Ju C, Liping Z., 'Circulating liver-specific miR-122 as a novel potential biomarker for diagnosis of cholestatic liver injury'.PLoS One. 2013 Sep 27;8(9):e73133. [52] Su TH, Liu CH, Liu CJ, Chen CL, Ting TT, Tseng TC, Chen PJ, Kao JH, Chen DS., 'Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C'.Proc Natl Acad Sci U S A. 2013 May 7;110(19):7844-9. [53] Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR., 'Treatment of HCV infection by targeting microRNA'.N Engl J Med. 2013 May 2;368(18):1685-94. [54] Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E., 'Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure'.Circulation. 2011 Oct 4;124(14):1537-47. [55] Garchow BG, Bartulos Encinas O, Leung YT, Tsao PY, Eisenberg RA, Caricchio R, Obad S, Petri A, Kauppinen S, Kiriakidou M., 'Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice'.EMBO Mol Med. 2011 Oct;3(10):605-15. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56024 | - |
| dc.description.abstract | 研究背景與目的： 慢性B型肝炎感染與肝細胞癌有密切的關係，而B型肝炎病毒量被認為是之中最重要的危險因子。目前已有許多微小核糖核酸研究發現miR-122在病毒複製和肝癌致癌機轉扮演重要角色。因此，我們的目的是研究循環miR-122和B型肝炎病毒量重複測量數值與肝細胞癌的關聯性。
材料於方法：本巢式病例對照研究樣本來自於1989至1992年間收取的B型肝炎帶原的男性公務人員世代研究，共納入89名肝癌患者與89名配對對照。進入研究時，我們收取個案的人口學、生活習慣和測量ALT數值，B肝病毒量則是每次回診時都會進行測量。我們使用反轉錄聚合酶連鎖反應和即時定量聚合酶連鎖增幅反應分析血清檢體中miR-122於各次重複測量的表現(於罹病前8.6、5.2和2.6 年)。統計分析使用條件式羅吉斯回歸進行分析。 結果：我們在各時點都觀察到miR-122的表現量與B肝病毒量有反向的關聯性，但在病例組或對照組中都未發現miR-122的表現量有隨時間變化的趨勢。不過從多變量分析的結果發現，在調整了年齡、ALT數值和B型肝炎基因型之後，於發病前5.2年的miR-122低度表現會提高2.54倍(95%CI=1.16－5.57)的肝癌罹患風險。但是我們並未在罹病前8.6年(OR= 1.9, 95% CI=0.92－3.80)或罹病前2.6年 (OR= 1.17, 95% CI=0.56－2.46)發現一樣的顯著結果。 結論：我們發現miR-122低表現量與較高的B型肝炎病毒量，也和肝細胞癌的風險增加有關，然而低表現量的時間點也可能是決定肝癌發生的重要因子。 | zh_TW |
| dc.description.abstract | Background & Aim: Chronic hepatitis B virus (HBV) infection is the predominant cause of hepatocellular carcinoma (HCC), and blood HBV DNA level is one of the most important risk factors for HBV-related HCC. Studies have shown a potential role of miR-122 in viral replication activity and in hepatocellular carcinogenesis. We aimed to investigate the association between circulating miR-122 expression and their concurrent HBV DNA levels, and the repeated measurements of the two factors in relation to subsequent development of HCC.
Materials & Methods: The study was conducted in 89 cases with HCC and 89 time-matched controls using a nested case-control design in a cohort study of male, hepatitis B surface antigen-positive civil servants who were recruited between 1989 and 1992. Information on demographics, lifestyle and blood alanine aminotransferase (ALT) were collected at study subjects’ entry into the cohort, while HBV-DNA data were obtained at study entry and follow-up. We used qRT-PCR to quantify the expression levels of miR-122 in serum samples drawn at thee follow-up visits (8.6, 5.2, and 2.6 years prior to the diagnosis of HCC). Conditional logistic regression was used for statistical analyses. Results: ∆Ct value of miR-122 was inversely correlated with HBV viral load at each of the three time-point survey. However, no apparent dynamic change across three measures of miR-122 was observed in either case or control group. When age, ALT level, and HBV genotype were adjusted for their potential confounding effects in multivariate analyses, down-regulation of miR-122 that occurred 5.2 years prior to the diagnosis of HCC was associated with a higher risk of HCC, showing an odds ratio of 2.54 (95%CI=1.16－5.57). Yet, we did not observe significant results from 8.6 years (adjusted-OR= 1.9, 95% CI=0.92－3.80) or 2.6 years (adjusted-OR= 1.17, 95% CI=0.56－2.46) prior to the diagnosis of HCC in the multivariable model. Conclusion: Down-regulation of circulating miR-122 expression was associated with higher HBV viral load and an increased risk of HCC, but the timing of the down-regulation might also be an important factor that determines subsequent HCC development. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:13:18Z (GMT). No. of bitstreams: 1 ntu-103-R01849002-1.pdf: 813344 bytes, checksum: 93dc248d018934f4051f60455f9d4a78 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract iii Introduction 1 Materials & Methods 8 Results 13 Discussion 16 Reference 21 Table 1 27 Table 2. 28 Table 3 29 Figure 1 30 Figure 2 31 Table 4 32 Table 5 33 | |
| dc.language.iso | en | |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | B型肝炎病毒量 | zh_TW |
| dc.subject | 微小核醣核酸-122 | zh_TW |
| dc.subject | MiR-122 | en |
| dc.subject | HBV viral load | en |
| dc.subject | HCC | en |
| dc.title | 微型核醣核酸-122和B型肝炎病毒量與肝細胞癌發展的相關性：巢式病例對照研究 | zh_TW |
| dc.title | Circulating miR-122, Hepatitis B Viral Load, and Risk of Hepatocellular Carcinoma: Nested Case-Control Study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 劉貞佑(Chen-Yu Liu),蔡孟勳(Mon-Hsun Tsai),林靖愉(Ching-Yu Lin) | |
| dc.subject.keyword | 微小核醣核酸-122,B型肝炎病毒量,肝細胞癌, | zh_TW |
| dc.subject.keyword | MiR-122,HBV viral load,HCC, | en |
| dc.relation.page | 33 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-18 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 794.28 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。